Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 13/20 | 0.41 |
| ▸ | DPP4 | P27487 | 5/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.35 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.35 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.35 |
| ▸ | ELOC | Q15369 | 2/20 | 0.34 |
| ▸ | ELOB | Q15370 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20419046 | 1.00 | VHL (0.41) | VHLDPP4DPP8DPP9HDAC3 | |
| SCHEMBL23183583 | 1.00 | VHL (0.41) | VHLDPP4DPP8DPP9HDAC3 | |
| SCHEMBL21554505 | 1.00 | VHL (0.41) | VHLDPP4DPP8DPP9HDAC3 | |
| SCHEMBL24474127 | 0.89 | VHL (0.40) | VHLHDAC3HDAC1HDAC2KDM1A | |
| SCHEMBL21759977 | 0.88 | VHL (0.38) | VHLDPP4DPP8DPP9HDAC3 | |
| SCHEMBL24558588 | 0.85 | DPP4 (0.36) | VHLDPP4DPP8DPP9HDAC3 | |
| SCHEMBL21554512 | 0.85 | VHL (0.43) | VHLDPP4DPP8DPP9ELOC | |
| SCHEMBL21554492 | 0.85 | VHL (0.43) | VHLDPP4DPP8DPP9ELOC | |
| SCHEMBL21554493 | 0.85 | VHL (0.43) | VHLDPP4DPP8DPP9ELOC | |
| SCHEMBL21554494 | 0.85 | VHL (0.43) | VHLDPP4DPP8DPP9ELOC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11541051-B2 | Compositions and methods for treating CDK4/6-mediated cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-01-03 | — | — | US | disclosed |
| US-20190336503-A1 | COMPOSITIONS AND METHODS FOR TREATING CDK4/6-MEDIATED CANCER | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2019-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190336503-A1 | COMPOSITIONS AND METHODS FOR TREATING CDK4/6-MEDIATED CANCER | CDK4, CDK6, CDK2 | VHL 216/4885DPP4 2207/4885DPP8 1856/4885 |
| US-11541051-B2 | Compositions and methods for treating CDK4/6-mediated cancer | CDK4, CDK6, CDK2 | VHL 216/4885DPP4 2207/4885DPP8 1856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.